Drugs / DIRIDAVUMAB
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT02016066 | Dec 2013 → Jan 2014 | — | Janssen Pharmaceutical K.K. | Withdrawn | No outcome recorded Stop: Business |
| Phase 1 | NCT01406418 | Feb → Nov 2013 | influenza | Crucell Holland BV | Completed | No outcome recorded |
| Phase 22 trials · 1 missed | ||||||
| Phase 2 | NCT02371668 | Feb 2015 → Nov 2018 | — | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | Missed primary |
| Phase 2 | NCT01992276 | Dec 2013 → Oct 2014 | influenza | Crucell Holland BV | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DIRIDAVUMAB | ChEMBL registry synonym — accepted as the source's own label CHEMBL3137350 ↗ |
| Known as | CR6261 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01406418 ↗ |
| Modality | Monoclonal antibody | “CR6261, a monoclonal antibody against influenza A viruses” NCT01406418 ↗ |
| Route | Intravenous | “Administered as a single 2-hour intravenous infusion” NCT01406418 ↗ |